These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36343410)

  • 61. The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470).
    Hamdouchi C; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Eessalu TE; Ficorilli JV; Marcelo MC; Otto KA; Wilbur KL; Lineswala JP; Piper JL; Coffey DS; Sweetana SA; Haas JV; Brooks DA; Pratt EJ; Belin RM; Deeg MA; Ma X; Cannady EA; Johnson JT; Yumibe NP; Chen Q; Maiti P; Montrose-Rafizadeh C; Chen Y; Reifel Miller A
    J Med Chem; 2016 Dec; 59(24):10891-10916. PubMed ID: 27749056
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Design, synthesis and structure-activity relationship studies of novel free fatty acid receptor 1 agonists bearing amide linker.
    Yang J; Li Z; Li H; Liu C; Wang N; Shi W; Liao C; Cai X; Huang W; Qian H
    Bioorg Med Chem; 2017 Apr; 25(8):2445-2450. PubMed ID: 28285923
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists.
    Wang X; Zhao T; Yang B; Li Z; Cui J; Dai Y; Qiu Q; Qiang H; Huang W; Qian H
    Bioorg Med Chem; 2015 Jan; 23(1):132-40. PubMed ID: 25481394
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Design, synthesis and biological activity of deuterium-based FFA1 agonists with improved pharmacokinetic profiles.
    Liu B; Deng L; Chen H; Liao R; Li Y; Zeng X; Deng F; Zhang L; Li Z
    Bioorg Med Chem Lett; 2019 Jun; 29(12):1471-1475. PubMed ID: 30992164
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Identification and pharmacological characterization of multiple allosteric binding sites on the free fatty acid 1 receptor.
    Lin DC; Guo Q; Luo J; Zhang J; Nguyen K; Chen M; Tran T; Dransfield PJ; Brown SP; Houze J; Vimolratana M; Jiao XY; Wang Y; Birdsall NJ; Swaminath G
    Mol Pharmacol; 2012 Nov; 82(5):843-59. PubMed ID: 22859723
    [TBL] [Abstract][Full Text] [Related]  

  • 66. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
    Coskun T; Sloop KW; Loghin C; Alsina-Fernandez J; Urva S; Bokvist KB; Cui X; Briere DA; Cabrera O; Roell WC; Kuchibhotla U; Moyers JS; Benson CT; Gimeno RE; D'Alessio DA; Haupt A
    Mol Metab; 2018 Dec; 18():3-14. PubMed ID: 30473097
    [TBL] [Abstract][Full Text] [Related]  

  • 67. GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus: Benefits and Challenges.
    Mohammad S
    Curr Drug Targets; 2016; 17(11):1292-300. PubMed ID: 26648068
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Structure-Activity Study of Dihydrocinnamic Acids and Discovery of the Potent FFA1 (GPR40) Agonist TUG-469.
    Christiansen E; Due-Hansen ME; Urban C; Merten N; Pfleiderer M; Karlsen KK; Rasmussen SS; Steensgaard M; Hamacher A; Schmidt J; Drewke C; Petersen RK; Kristiansen K; Ullrich S; Kostenis E; Kassack MU; Ulven T
    ACS Med Chem Lett; 2010 Oct; 1(7):345-9. PubMed ID: 24900217
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The effects of TAK-875, a selective G protein-coupled receptor 40/free fatty acid 1 agonist, on insulin and glucagon secretion in isolated rat and human islets.
    Yashiro H; Tsujihata Y; Takeuchi K; Hazama M; Johnson PR; Rorsman P
    J Pharmacol Exp Ther; 2012 Feb; 340(2):483-9. PubMed ID: 22106100
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Drug discovery opportunities and challenges at g protein coupled receptors for long chain free Fatty acids.
    Holliday ND; Watson SJ; Brown AJ
    Front Endocrinol (Lausanne); 2011; 2():112. PubMed ID: 22649399
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Design, synthesis and structure-activity relationship studies of novel phenoxyacetamide-based free fatty acid receptor 1 agonists for the treatment of type 2 diabetes.
    Li Z; Wang X; Xu X; Yang J; Qiu Q; Qiang H; Huang W; Qian H
    Bioorg Med Chem; 2015 Oct; 23(20):6666-72. PubMed ID: 26420383
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Discovery of AM-1638: A Potent and Orally Bioavailable GPR40/FFA1 Full Agonist.
    Brown SP; Dransfield PJ; Vimolratana M; Jiao X; Zhu L; Pattaropong V; Sun Y; Liu J; Luo J; Zhang J; Wong S; Zhuang R; Guo Q; Li F; Medina JC; Swaminath G; Lin DC; Houze JB
    ACS Med Chem Lett; 2012 Sep; 3(9):726-30. PubMed ID: 24900539
    [TBL] [Abstract][Full Text] [Related]  

  • 73. G-protein coupled receptor 40 agonists as novel therapeutics for type 2 diabetes.
    Choi YJ; Shin D; Lee JY
    Arch Pharm Res; 2014 Apr; 37(4):435-9. PubMed ID: 24234912
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Treatment with CNX-011-67, a novel GPR40 agonist, delays onset and progression of diabetes and improves beta cell preservation and function in male ZDF rats.
    Gowda N; Dandu A; Singh J; Biswas S; Raghav V; Lakshmi MN; Shilpa PC; Sunil V; Reddy A; Sadasivuni M; Aparna K; Verma MK; Moolemath Y; Anup MO; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2013 May; 14():28. PubMed ID: 23692921
    [TBL] [Abstract][Full Text] [Related]  

  • 75. CNX-011-67, a novel GPR40 agonist, enhances glucose responsiveness, insulin secretion and islet insulin content in n-STZ rats and in islets from type 2 diabetic patients.
    Sunil V; Verma MK; Oommen AM; Sadasivuni M; Singh J; Vijayraghav DN; Chandravanshi B; Shetty J; Biswas S; Dandu A; Moolemath Y; Venkataranganna MV; Somesh BP; Jagannath MR
    BMC Pharmacol Toxicol; 2014 Mar; 15():19. PubMed ID: 24666736
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of LY3104607: A Potent and Selective G Protein-Coupled Receptor 40 (GPR40) Agonist with Optimized Pharmacokinetic Properties to Support Once Daily Oral Treatment in Patients with Type 2 Diabetes Mellitus.
    Hamdouchi C; Maiti P; Warshawsky AM; DeBaillie AC; Otto KA; Wilbur KL; Kahl SD; Patel Lewis A; Cardona GR; Zink RW; Chen K; Cr S; Lineswala JP; Neathery GL; Bouaichi C; Diseroad BA; Campbell AN; Sweetana SA; Adams LA; Cabrera O; Ma X; Yumibe NP; Montrose-Rafizadeh C; Chen Y; Miller AR
    J Med Chem; 2018 Feb; 61(3):934-945. PubMed ID: 29236497
    [TBL] [Abstract][Full Text] [Related]  

  • 77. GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit.
    Mancini AD; Poitout V
    Diabetes Obes Metab; 2015 Jul; 17(7):622-9. PubMed ID: 25604916
    [TBL] [Abstract][Full Text] [Related]  

  • 78. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.
    Leifke E; Naik H; Wu J; Viswanathan P; Demanno D; Kipnes M; Vakilynejad M
    Clin Pharmacol Ther; 2012 Jul; 92(1):29-39. PubMed ID: 22669289
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Non-Acidic Free Fatty Acid Receptor 4 Agonists with Antidiabetic Activity.
    Azevedo CM; Watterson KR; Wargent ET; Hansen SV; Hudson BD; Kępczyńska MA; Dunlop J; Shimpukade B; Christiansen E; Milligan G; Stocker CJ; Ulven T
    J Med Chem; 2016 Oct; 59(19):8868-8878. PubMed ID: 27570890
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Design, synthesis, and biological activity of potent and orally available G protein-coupled receptor 40 agonists.
    Sasaki S; Kitamura S; Negoro N; Suzuki M; Tsujihata Y; Suzuki N; Santou T; Kanzaki N; Harada M; Tanaka Y; Kobayashi M; Tada N; Funami M; Tanaka T; Yamamoto Y; Fukatsu K; Yasuma T; Momose Y
    J Med Chem; 2011 Mar; 54(5):1365-78. PubMed ID: 21319751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.